RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS One, 4 (10). e7302. ISSN 1932-620
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate ...
BACKGROUND: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of Afric...
BACKGROUND: GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of Pl...
The target delivery channel of RTS,S candidate malaria vaccines in malaria-endemic countries in Afri...
in infants and young children 5–17 months of age in Ghana.. The primary outcome measure was the occ...
BACKGROUND: The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being develo...
circumsporozoite (CSP) antigen-specific antibody and T cell responses which...
The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporo...
BACKGROUND: The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivere...
The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and t...
Background The RTS,S/AS01 malaria vaccine candidate is being evaluated for implementation. Methods W...
A malaria vaccine could be an important addition to current control strategies. We report the safety...
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up ha...
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate ...
BACKGROUND: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of Afric...
BACKGROUND: GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of Pl...
The target delivery channel of RTS,S candidate malaria vaccines in malaria-endemic countries in Afri...
in infants and young children 5–17 months of age in Ghana.. The primary outcome measure was the occ...
BACKGROUND: The Plasmodium falciparum pre-erythrocytic stage candidate vaccine RTS,S is being develo...
circumsporozoite (CSP) antigen-specific antibody and T cell responses which...
The malaria vaccine candidate antigen RTS,S includes parts of the pre-erythrocytic stage circumsporo...
BACKGROUND: The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivere...
The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and t...
Background The RTS,S/AS01 malaria vaccine candidate is being evaluated for implementation. Methods W...
A malaria vaccine could be an important addition to current control strategies. We report the safety...
Background An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria...
BACKGROUND: RTS,S/AS01E is the lead candidate malaria vaccine. We recently showed efficacy against c...
The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up ha...
BACKGROUND\ud \ud An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate ...
BACKGROUND: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of Afric...
BACKGROUND: GMZ2 is a recombinant protein malaria vaccine, comprising two blood-stage antigens of Pl...
.jpg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG